Amarantus BioScience Holdings (OTC: AMBS) is a biotechnology company developing treatments and diagnostics for neurological and orphan diseases. The company has a worldwide license to intellectual property rights associated to Engineered Skin Substitute (ESS), an orphan drug that provides autologous full thickness skin replacement for the treatment of adult severe burns. AMBS also owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic factor (MANF) which can serve as a treatment for orphan ophthalmic disorders. For more information, visit the company’s website at www.amarantus.com